---
title: "Estrella Immunopharma (ESLA.US) — 財務報表"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ESLA.US/norm.md"
symbol: "ESLA.US"
name: "Estrella Immunopharma"
parent: "https://longbridge.com/zh-HK/quote/ESLA.US.md"
datetime: "2026-03-18T05:44:21.723Z"
locales:
  - [en](https://longbridge.com/en/quote/ESLA.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ESLA.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ESLA.US/norm.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/ESLA.US/norm.md) | [简体中文](https://longbridge.com/zh-CN/quote/ESLA.US/norm.md)


# Estrella Immunopharma (ESLA.US) — 財務報表

## 損益表 (USD)

| 指標 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.1294 | -0.1533 | -0.0581 | -0.1082 | -0.0933 |
| ROE | 241.10% | 559.69% | - | -247.55% | - |
| Revenue | - | - | - | - | - |
| Net income | -4.80M | -5.54M | -2.10M | -3.95M | -3.38M |
| Operating income | -4.80M | -5.54M | -2.10M | -3.95M | -3.38M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## 資產負債表 (USD)

| 指標 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| A&L | 3.52M | 2.98M | 2.44M | 4.45M | - |
| Leverage | -0.3582 | -0.4890 | -1.33 | 1.04 | - |
| BVPS | -0.2605 | -0.1644 | -0.0506 | 0.1178 | - |
| Turnover | - | - | - | - | - |
| Cash & STI | 1.63M | 1.32M | 421473.00 | 4.17M | - |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -1.62M | -1.31M | -411473.00 | -4.16M | - |

## 現金流量表 (USD)

| 指標 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -727332.00 | -414879.00 | -465981.00 | -291513.00 | -2.22M |
| Investing CF | - | - | - | 0.0000 | - |
| Financing CF | 1.04M | 1.31M | -29462.00 | -270349.00 | -150465.00 |
| Free CF | 1.20M | 1.86M | - | 1.19M | - |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | 0.0000 | - |
| CapEx | - | - | - | - | - |